Bristol Myers Squibb

Phase III clinical trials cost between $19 million and over $100 million per trial and involve complex logistics across partners and sites. BMS needed to reduce development timelines and costly inefficiencies to bring breakthrough therapies to patients faster.

In partnership with Accenture, BMS implemented over 30 generative AI solutions across R&D, Global Product Development & Supply, and Commercialization. The centerpiece is 'Workbench,' a clinical trial accelerator that fuses AI-driven insights with real-time operational data, delivers role-based recommendations, anticipates issues, and captures institutional knowledge across trial teams.

The approach accelerated BMS clinical trials by months and increased reaction speed to prevent issues. The platform was adopted by over 30 top-priority clinical trial teams and became BMS's official platform for priority trials, standardizing best practices across the organization.

• Generative AI integrated with real-time operational data can compress Phase III clinical trial timelines by months at scale.
• Role-contextual, personalized platforms drive rapid adoption — users grew 9x in just three months without mandated rollout.
• AI platforms that capture and forward institutional knowledge help large organizations maintain execution consistency across distributed trial teams.